Cytrx's tamibarotene achieves molecular complete remission in advanced acute promyelocytic leukemia
Links shared publicly online about this topic.
- 1,002total visits
Cytrx's tamibarotene achieves molecular complete remission in advanced acute promyelocytic leukemia
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that a 44-year-old female patient with advanced acute promyelocytic leukemia (APL) achieved molecular complete remission with no evidence of disease in the blood cells and/or bone marrow following treatment with CytRx's oncology drug candidate tamibarotene.
View full resource at news-medical.net
Tags: Cancer, Leukemia, Prostate Cancer, Prostate, Men's Health, Women's Health, Oncology, disease
Most Recently Shared on July 23, 2010 at 12:58 pm By:
Prostate Cancer: Cytrx’s tamibarotene achieves molecular complete remission in advanced acute promyelocytic leukem... http://bit.ly/d4RlSv
Also Shared By:
CytRx's Tamibarotene Eradicates Cancer in Advanced Acute Promyelocytic Leukemia After Failure of Other Therapies - FierceBiotech
fiercebiotech.com — “CytRx's Tamibarotene Eradicates Cancer in Advanced Acute Promyelocytic Leukemia After Failure of Other TherapiesTamibarotene-Treated Leukemia Patient Achieves Molecular Complete Remission Following Read more...” View full resource at fiercebiotech.com
Most Recently Shared on July 23, 2010 at 1:26 am By:
CytRx's tamibarotene eradicates cancer in advanced acute promyelocytic leukemia after failure of other therapies. http://bit.ly/9z7AoH
Advertisement
News-Medical.Net
@NewsMedical
Cytrx’s tamibarotene achieves molecular complete remission in advanced acute promyelocytic leukemia: CytRx Corpora... http://bit.ly/d4RlSv
1 year ago...